A Phase 2 interventional study of Nivolumab and Ipilimumab in Various Advanced Cancer, sponsored by Bristol-Myers Squibb. Completed at 54 sites in 15 countries. Open to participants aged 6 Months to 21 Years. Per ClinicalTrials.gov, last updated 2022-08-09.
Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to determine the safety and effectiveness of nivolumab alone and in combination with ipilimumab in pediatric patients with high grade primary central nervous system (CNS) malignancies.
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol defined inclusion/exclusion criteria apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: Nivolumab
Biological: Nivolumab · Biological: Ipilimumab
Specified dose on specified days
Also known as: Opdivo, BMS-936558
Specified dose on specified days
Also known as: Yervoy, BMS-734016
Number of Safety Lead-In Participants With Dose Limiting Toxicities (DLTs)
A dose-limiting toxicity (DLT) is defined as a drug-related AE occurring in the first 6 weeks of study treatment. A participant was considered evaluable for a DLT if study treatment was delayed \> 2 weeks or was discontinued due to a related Adverse Event (AE), or if planned study treatment (3 doses of nivolumab in Module A, 2 doses of nivolumab plus ipilimumab in Module B) was administered and safety evaluation after 6 weeks on study is available to the study steering committee (SSC).
Time frame: up to 6 weeks post-dosing
Number of Safety Lead-In Participants With Serious Adverse Events (SAEs)
The number of Safety Lead-In Participants who experienced a Serious Adverse Event (SAE) during the course of the study.
Time frame: up to 6 weeks post-dosing
Number of Safety Lead-In Participants With Adverse Events (AEs) Leading to Discontinuation
The number of Safety Lead-In Participants who experienced an Adverse Event (AE) during the course of the study that lead to discontinuation of study therapy.
Time frame: From first dose to 30 days post-last dose (up to approximately 6 weeks)
Overall Survival (OS), Cohort 1 Only
Overall survival (OS) is defined as the time between the date of diagnosis and the date of death in Cohort 1.
Time frame: up to approximately 42 months
Progression-Free Survival (PFS), Cohorts 2-4
Progression-free survival (PFS) is defined as the time from first dose to the date of the first documented tumor progression or death due to any cause.
Time frame: up to approximately 42 months
Progression-Free Survival (PFS), Cohort 5 Only
Progression-free survival (PFS) is defined as the time from first dose to the date of the first documented tumor progression or death due to any cause.
Time frame: up to approximately 42 months
Progression-Free Survival (PFS), Cohort 1 Only
Progression-free survival (PFS) is defined as the time from first dose to the date of the first documented tumor progression or death due to any cause. Progression is defined as: * ≥ 25% increase in sum of the products of perpendicular diameters of enhancing lesions compared with the smallest tumor measurement * Significant increase in T2 or fast fluid-attenuated inversion recovery (FLAIR) non-enhancing lesions on stable or increasing doses of corticosteroids * Any new lesion * Clear clinical deterioration not attributable to other causes apart from the tumor * Failure to return for evaluation as a result of death or deteriorating condition * Clear progression of non-measurable disease
Time frame: From first dose to the date of the first documented tumor progression or death due to any cause (up to approximately 55 months)
Overall Survival at 12 Months (OS12), Cohorts 1-4
Overall survival at 12 months (OS12) is defined as the percentage of participants who are alive at 12 months, measured as the survival rate at 12 months from Kaplan-Meier product limit cumulative probability.
Time frame: From first dose to up to 12 months after first dose
Progression-Free Survival at 6 Months (PFS6), Cohorts 2-5
Progression-free survival at 6 months (PFS6) is defined as the percentage of participants who are progression free and alive at 6 months following first dose date, measured as the survival rate at 6 months from Kaplan-Meier product limit cumulative probability of progression free. Progression is defined as: * ≥ 25% increase in sum of the products of perpendicular diameters of enhancing lesions compared with the smallest tumor measurement * Significant increase in T2 or fast fluid-attenuated inversion recovery (FLAIR) non-enhancing lesions on stable or increasing doses of corticosteroids * Any new lesion * Clear clinical deterioration not attributable to other causes apart from the tumor * Failure to return for evaluation as a result of death or deteriorating condition * Clear progression of non-measurable disease
Time frame: From first dose to up to 6 months after first dose
Overall Survival (OS), Cohorts 2-5
Overall survival (OS) is defined as the time between date of first dose and the date of death for Cohorts 2-5.
Time frame: From first dose to the date of death (up to approximately 55 months)
Number of Treated Participants With Adverse Events (AEs)
The number of treated participants who experienced an Adverse Event (AE) during the course of the study. An AE is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study drug and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug.
Time frame: From first dose to 30 days post-last dose (up to approximately an average of 3 months and a maximum of 51 months)
Number of Treated Participants With Serious Adverse Events (SAEs)
The number of treated participants who experienced a Serious Adverse Event (SAE) during the course of the study. SAE is defined as any untoward medical occurrence that, at any dose: * Results in death * Is life-threatening * Requires inpatient hospitalization or causes prolongation of existing hospitalization * Results in persistent or significant disability/incapacity * Is a congenital anomaly/birth defect * Is an important medical event Note: The reporting timeframe of the SAEs for this Outcome Measure (first dose to 30 days post last dose) differs than that of the reporting timeframe of the SAEs reported under the AE section of the results form (first dose to 100 days post last dose) and thus, the data in each table of SAEs reflects the specific timeframe applied.
Time frame: From first dose to 30 days post-last dose (up to approximately an average of 3 months and a maximum of 51 months)
Number of Treated Participants With Drug-Related Adverse Events
The number of treated participants who experienced a Drug-Related Adverse Event during the course of the study. An AE is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study drug and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug.
Time frame: From first dose to 30 days post-last dose (up to approximately an average of 3 months and a maximum of 51 months)
Number of Treated Participants With Adverse Events Leading to Discontinuation
The number of treated participants who experienced an Adverse Event leading to discontinuation during the course of the study. An AE is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study drug and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug.
Time frame: From first dose to 30 days post-last dose (up to approximately an average of 3 months and a maximum of 51 months)
Number of Treated Participant Deaths
The number of treated participants who died during the course of the study.
Time frame: From first dose to the date of death (up to approximately 55 months)
Number of Treated Participant With Laboratory Abnormalities - Liver
The number of treated participants who experienced a laboratory abnormality of the liver during the course of the study. Aspartate aminotransferase (AST) Alanine aminotransferase (ALT) Upper Limit of Normal (ULN) Units per Liter (U/L) Results reported in International System of Units (SI)
Time frame: From first dose to 30 days post-last dose (up to approximately an average of 3 months and a maximum of 51 months)
Number of Treated Participant With Laboratory Abnormalities - Thyroid
The number of treated participants who experienced a laboratory abnormality of the thyroid during the course of the study. Free T3 (FT3) Free T4 (FT4) Thyroid stimulating hormone (TSH) Lower Limit of Normal (LLN) Upper limit of normal (ULN) Milliunits per Liter (mlU/L) Results reported in International System of Units (SI)
Time frame: From first dose to 30 days post-last dose (up to approximately an average of 3 months and a maximum of 51 months)
| Milestone | Arm A1 | Arm B1 | Arm A2 | Arm B2 | Arm A3 | Arm B3 | Arm A4 | Arm B4 | Arm A5 | Arm B5 |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 23 | 22 | 16 | 15 | 15 | 15 | 12 | 10 | 19 | 19 |
| Completed | 0 | 12 | 0 | 1 | 0 | 9 | 0 | 6 | 0 | 4 |
| Not completed | 23 | 10 | 16 | 14 | 15 | 6 | 12 | 4 | 19 | 15 |
| Withdrew: Disease progression | 19 | 7 | 12 | 7 | 12 | 3 | 6 | 3 | 15 | 8 |
| Withdrew: Study drug toxicity | 2 | 2 | 1 | 2 | 1 | 1 | 3 | 0 | 3 | 3 |
| Withdrew: Other reasons | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 |
| Withdrew: Subject request to discontinue therapy | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 0 |
| Withdrew: Not reported | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 1 |
| Withdrew: Adverse event unrelated to drug | 0 | 0 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 1 |
| Withdrew: Participant withdrew consent | 0 | 1 | 0 | 2 | 1 | 0 | 0 | 0 | 0 | 2 |
| Withdrew: Administrative reason by sponsor | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
A dose-limiting toxicity (DLT) is defined as a drug-related AE occurring in the first 6 weeks of study treatment. A participant was considered evaluable for a DLT if study treatment was delayed \> 2 weeks or was discontinued due to a related Adverse Event (AE), or if planned study treatment (3 doses of nivolumab in Module A, 2 doses of nivolumab plus ipilimumab in Module B) was administered and safety evaluation after 6 weeks on study is available to the study steering committee (SSC).
| Number of participants | Arm A1, Safety Lead-in | Arms A2-A5, Safety Lead-in | Arms B2-B5, Safety Lead-in |
|---|---|---|---|
| Number of Safety Lead-In Participants With Dose Limiting Toxicities (DLTs) | 0 | 0 | 0 |
The number of Safety Lead-In Participants who experienced a Serious Adverse Event (SAE) during the course of the study.
| Number of participants | Arm A1, Safety Lead-in | Arms A2-A5, Safety Lead-in | Arms B2-B5, Safety Lead-in |
|---|---|---|---|
| Number of Safety Lead-In Participants With Serious Adverse Events (SAEs) | 7 | 6 | 8 |
The number of Safety Lead-In Participants who experienced an Adverse Event (AE) during the course of the study that lead to discontinuation of study therapy.
| Participants | Arm A1, Safety Lead-in | Arms A2-A5, Safety Lead-in | Arms B2-B5, Safety Lead-in |
|---|---|---|---|
| Number of Safety Lead-In Participants With Adverse Events (AEs) Leading to Discontinuation | 3 | 4 | 2 |
Overall survival (OS) is defined as the time between the date of diagnosis and the date of death in Cohort 1.
| months | Arm A1 | Arm B1 |
|---|---|---|
| Overall Survival (OS), Cohort 1 Only | 11.66 (10.32 to 16.46) | 10.78 (9.13 to 15.77) |
Progression-free survival (PFS) is defined as the time from first dose to the date of the first documented tumor progression or death due to any cause.
| months | Arm A2 | Arm B2 | Arm A3 | Arm B3 | Arm A4 | Arm B4 |
|---|---|---|---|---|---|---|
| Progression-Free Survival (PFS), Cohorts 2-4 | 1.74 (1.35 to 2.73) | 1.31 (1.18 to 1.45) | 1.38 (1.22 to 1.38) | 2.76 (1.48 to 4.53) | 1.41 (1.41 to 2.60) | 4.60 (1.41 to 5.39) |
Progression-free survival (PFS) is defined as the time from first dose to the date of the first documented tumor progression or death due to any cause.
| months | Arm A5 | Arm B5 |
|---|---|---|
| Progression-Free Survival (PFS), Cohort 5 Only | 1.22 (1.08 to 1.31) | 1.61 (1.31 to 3.45) |
Progression-free survival (PFS) is defined as the time from first dose to the date of the first documented tumor progression or death due to any cause. Progression is defined as: * ≥ 25% increase in sum of the products of perpendicular diameters of enhancing lesions compared with the smallest tumor measurement * Significant increase in T2 or fast fluid-attenuated inversion recovery (FLAIR) non-enhancing lesions on stable or increasing doses of corticosteroids * Any new lesion * Clear clinical deterioration not attributable to other causes apart from the tumor * Failure to return for evaluation as a result of death or deteriorating condition * Clear progression of non-measurable disease
| Months | Arm A1 | Arm B1 |
|---|---|---|
| Progression-Free Survival (PFS), Cohort 1 Only | 6.21 (3.75 to 6.54) | 4.53 (2.99 to 6.44) |
Overall survival at 12 months (OS12) is defined as the percentage of participants who are alive at 12 months, measured as the survival rate at 12 months from Kaplan-Meier product limit cumulative probability.
| Percentage of participants | Arm A1 | Arm B1 | Arm A2 | Arm B2 | Arm A3 | Arm B3 | Arm A4 | Arm B4 |
|---|---|---|---|---|---|---|---|---|
| Overall Survival at 12 Months (OS12), Cohorts 1-4 | 47.3 (25.2 to 66.5) | 42.9 (21.9 to 62.3) | 37.5 (15.4 to 59.8) | 32.8 (10.5 to 57.6) | 38.9 (14.3 to 63.2) | 86.7 (56.4 to 96.5) | 41.7 (15.2 to 66.5) | 44.4 (13.6 to 71.9) |
Progression-free survival at 6 months (PFS6) is defined as the percentage of participants who are progression free and alive at 6 months following first dose date, measured as the survival rate at 6 months from Kaplan-Meier product limit cumulative probability of progression free. Progression is defined as: * ≥ 25% increase in sum of the products of perpendicular diameters of enhancing lesions compared with the smallest tumor measurement * Significant increase in T2 or fast fluid-attenuated inversion recovery (FLAIR) non-enhancing lesions on stable or increasing doses of corticosteroids * Any new lesion * Clear clinical deterioration not attributable to other causes apart from the tumor * Failure to return for evaluation as a result of death or deteriorating condition * Clear progression of non-measurable disease
| Percentage of participants | Arm A2 | Arm B2 | Arm A3 | Arm B3 | Arm A4 | Arm B4 | Arm A5 | Arm B5 |
|---|---|---|---|---|---|---|---|---|
| Progression-Free Survival at 6 Months (PFS6), Cohorts 2-5 | 9.4 (0.7 to 31.8) | 14.3 (2.3 to 36.6) | 0 (NA to NA) | 20.0 (4.9 to 42.4) | 20.0 (3.1 to 47.5) | 11.4 (0.6 to 39.5) | 5.3 (0.4 to 21.4) | 14.0 (2.8 to 34.1) |
Overall survival (OS) is defined as the time between date of first dose and the date of death for Cohorts 2-5.
| Months | Arm A2 | Arm B2 | Arm A3 | Arm B3 | Arm A4 | Arm B4 | Arm A5 | Arm B5 |
|---|---|---|---|---|---|---|---|---|
| Overall Survival (OS), Cohorts 2-5 | 6.67 (2.99 to 14.62) | 6.47 (2.14 to 13.17) | 7.36 (2.46 to 30.23) | 22.21 (13.77 to NA) | 5.70 (1.81 to NA) | 9.82 (2.50 to NA) | 5.91 (1.97 to 7.98) | 8.48 (3.45 to 17.28) |
The number of treated participants who experienced an Adverse Event (AE) during the course of the study. An AE is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study drug and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug.
| Participants | Arm A1 | Arm B1 | Arm A2 | Arm B2 | Arm A3 | Arm B3 | Arm A4 | Arm B4 | Arm A5 | Arm B5 |
|---|---|---|---|---|---|---|---|---|---|---|
| Number of Treated Participants With Adverse Events (AEs) | 23 | 21 | 15 | 14 | 14 | 15 | 12 | 10 | 18 | 18 |
The number of treated participants who experienced a Serious Adverse Event (SAE) during the course of the study. SAE is defined as any untoward medical occurrence that, at any dose: * Results in death * Is life-threatening * Requires inpatient hospitalization or causes prolongation of existing hospitalization * Results in persistent or significant disability/incapacity * Is a congenital anomaly/birth defect * Is an important medical event Note: The reporting timeframe of the SAEs for this Outcome Measure (first dose to 30 days post last dose) differs than that of the reporting timeframe of the SAEs reported under the AE section of the results form (first dose to 100 days post last dose) and thus, the data in each table of SAEs reflects the specific timeframe applied.
| Participants | Arm A1 | Arm B1 | Arm A2 | Arm B2 | Arm A3 | Arm B3 | Arm A4 | Arm B4 | Arm A5 | Arm B5 |
|---|---|---|---|---|---|---|---|---|---|---|
| Number of Treated Participants With Serious Adverse Events (SAEs) | 10 | 14 | 10 | 9 | 6 | 7 | 7 | 5 | 13 | 14 |
The number of treated participants who experienced a Drug-Related Adverse Event during the course of the study. An AE is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study drug and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug.
| Participants | Arm A1 | Arm B1 | Arm A2 | Arm B2 | Arm A3 | Arm B3 | Arm A4 | Arm B4 | Arm A5 | Arm B5 |
|---|---|---|---|---|---|---|---|---|---|---|
| Number of Treated Participants With Drug-Related Adverse Events | 14 | 16 | 12 | 8 | 6 | 11 | 6 | 6 | 11 | 10 |
The number of treated participants who experienced an Adverse Event leading to discontinuation during the course of the study. An AE is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study drug and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug.
| Participants | Arm A1 | Arm B1 | Arm A2 | Arm B2 | Arm A3 | Arm B3 | Arm A4 | Arm B4 | Arm A5 | Arm B5 |
|---|---|---|---|---|---|---|---|---|---|---|
| Number of Treated Participants With Adverse Events Leading to Discontinuation | 4 | 7 | 3 | 5 | 2 | 3 | 6 | 1 | 6 | 8 |
The number of treated participants who died during the course of the study.
| Participants | Arm A1 | Arm B1 | Arm A2 | Arm B2 | Arm A3 | Arm B3 | Arm A4 | Arm B4 | Arm A5 | Arm B5 |
|---|---|---|---|---|---|---|---|---|---|---|
| Number of Treated Participant Deaths | 18 | 18 | 12 | 13 | 12 | 11 | 9 | 7 | 18 | 15 |
The number of treated participants who experienced a laboratory abnormality of the liver during the course of the study. Aspartate aminotransferase (AST) Alanine aminotransferase (ALT) Upper Limit of Normal (ULN) Units per Liter (U/L) Results reported in International System of Units (SI)
| Participants | Arm A1 | Arm B1 | Arm A2 | Arm B2 | Arm A3 | Arm B3 | Arm A4 | Arm B4 | Arm A5 | Arm B5 |
|---|---|---|---|---|---|---|---|---|---|---|
| ALT OR AST > 3XULN | 3 | 7 | 2 | 0 | 0 | 3 | 1 | 1 | 3 | 2 |
| ALT OR AST > 5XULN | 2 | 4 | 1 | 0 | 0 | 1 | 0 | 1 | 2 | 2 |
| ALT OR AST > 10XULN | 2 | 1 | 1 | 0 | 0 | 1 | 0 | 1 | 2 | 2 |
| ALT OR AST > 20XULN | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| TOTAL BILIRUBIN > 2XULN | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| ALP > 1.5XULN | 0 | 0 | 0 | — | — | — | — | — | 0 | 1 |
| ALT or AST > 3xULN w/ Tbili > 1.5*ULN within 1 day | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| ALT or AST > 3xULN w/ Tbili > 1.5*ULN within 30 days | 0 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| ALT or AST > 3xULN w/ Tbili > 2*ULN within 1 day | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| ALT or AST > 3xULN w/ Tbili > 2*ULN within 30 days | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
The number of treated participants who experienced a laboratory abnormality of the thyroid during the course of the study. Free T3 (FT3) Free T4 (FT4) Thyroid stimulating hormone (TSH) Lower Limit of Normal (LLN) Upper limit of normal (ULN) Milliunits per Liter (mlU/L) Results reported in International System of Units (SI)
| Participants | Arm A1 | Arm B1 | Arm A2 | Arm B2 | Arm A3 | Arm B3 | Arm A4 | Arm B4 | Arm A5 | Arm B5 |
|---|---|---|---|---|---|---|---|---|---|---|
| TSH > ULN | 2 | 1 | 3 | 1 | 3 | 7 | 2 | 3 | 1 | 5 |
| TSH > ULN, WITH TSH <= ULN AT BASELINE | 2 | 1 | 2 | 1 | 0 | 7 | 1 | 3 | 1 | 2 |
| TSH > ULN, WITH AT LEAST ONE FT3/FT4 TEST < LLN | 1 | 1 | 1 | 1 | 1 | 6 | 2 | 2 | 0 | 2 |
| TSH > ULN, WITH ALL OTHER FT3/FT4 TEST >= LLN | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 3 |
| TSH > ULN, WITH FT3/FT4 TEST MISSING | 1 | 0 | 1 | 0 | 2 | 1 | 0 | 1 | 0 | 0 |
| TSH < LLN | 3 | 7 | 2 | 2 | 0 | 3 | 0 | 0 | 0 | 1 |
| TSH < LLN, WITH TSH >= LLN AT BASELINE | 3 | 6 | 1 | 2 | 0 | 1 | 0 | 0 | 0 | 1 |
| TSH<LLN, LLN WITH AT LEAST ONE FT3/FT4 TEST>ULN | 0 | 1 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 |
| TSH < LLN, WITH ALL OTHER FT3/FT4 TEST <= ULN | 1 | 2 | 1 | 2 | 0 | 1 | 0 | 0 | 0 | 1 |
| TSH < LLN, WITH FT3/FT4 TEST MISSING | 2 | 4 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Overall survival (OS) is defined as the time between the date of diagnosis and the date of death in Cohort 1. Note: This outcome measure represents an updated version of the primary endpoint to include additional data collection that has occurred after the primary completion date. (Assessments were made until 17-Jan-2022).
| Months | Arm A1 | Arm B1 |
|---|---|---|
| Overall Survival (OS), Cohort 1 Only - Extended Collection | 11.66 (10.32 to 23.49) | 10.78 (9.13 to 15.77) |
Progression-free survival (PFS) is defined as the time from first dose to the date of the first documented tumor progression or death due to any cause. Note: This outcome measure represents an updated version of the primary endpoint to include additional data collection that has occurred after the primary completion date. (Assessments were made until 17-Jan-2022). Progression is defined as: * ≥ 25% increase in sum of the products of perpendicular diameters of enhancing lesions compared with the smallest tumor measurement * Significant increase in T2 or fast fluid-attenuated inversion recovery (FLAIR) non-enhancing lesions on stable or increasing doses of corticosteroids * Any new lesion * Clear clinical deterioration not attributable to other causes apart from the tumor * Failure to return for evaluation as a result of death or deteriorating condition * Clear progression of non-measurable disease
| Months | Arm A2 | Arm B2 | Arm A3 | Arm B3 | Arm A4 | Arm B4 |
|---|---|---|---|---|---|---|
| Progression-Free Survival (PFS), Cohorts 2-4 - Extended Collection | 1.74 (1.35 to 2.73) | 1.38 (1.22 to 1.48) | 1.38 (1.22 to 1.38) | 2.69 (1.48 to 4.53) | 1.41 (1.38 to 2.60) | 4.60 (1.41 to 5.39) |
Progression-free survival (PFS) is defined as the time from first dose to the date of the first documented tumor progression or death due to any cause. Note: This outcome measure represents an updated version of the primary endpoint to include additional data collection that has occurred after the primary completion date. (Assessments were made until 17-Jan-2022). Progression is defined as: * ≥ 25% increase in sum of the products of perpendicular diameters of enhancing lesions compared with the smallest tumor measurement * Significant increase in T2 or fast fluid-attenuated inversion recovery (FLAIR) non-enhancing lesions on stable or increasing doses of corticosteroids * Any new lesion * Clear clinical deterioration not attributable to other causes apart from the tumor * Failure to return for evaluation as a result of death or deteriorating condition * Clear progression of non-measurable disease
| Months | Arm A5 | Arm B5 |
|---|---|---|
| Progression-Free Survival (PFS), Cohort 5 Only - Extended Collection | 1.22 (1.08 to 1.31) | 1.61 (1.31 to 3.45) |
Collected over All-cause mortality was assessed from first dose to study completion (up to approximately 55 months). SAEs and Other AEs were monitored from first dose to 100 days after last dose (up to an average of 5 months and to a maximum of 53 months).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm A1 | 18/23 (78.3%) | 17/23 (73.9%) | 22/23 (95.7%) |
| Arm B1 | 18/22 (81.8%) | 16/22 (72.7%) | 21/22 (95.5%) |
| Arm A2 | 12/16 (75%) | 13/16 (81.3%) | 15/16 (93.8%) |
| Arm B2 | 13/15 (86.7%) | 12/15 (80%) | 14/15 (93.3%) |
| Arm A3 | 12/15 (80%) | 7/15 (46.7%) | 14/15 (93.3%) |
| Arm B3 | 11/15 (73.3%) | 10/15 (66.7%) | 14/15 (93.3%) |
| Arm A4 | 9/12 (75%) | 11/12 (91.7%) | 11/12 (91.7%) |
| Arm B4 | 7/10 (70%) | 6/10 (60%) | 10/10 (100%) |
| Arm A5 | 18/19 (94.7%) | 14/19 (73.7%) | 18/19 (94.7%) |
| Arm B5 | 15/19 (78.9%) | 15/19 (78.9%) | 18/19 (94.7%) |
| Event | Arm A1 | Arm B1 | Arm A2 | Arm B2 | Arm A3 | Arm B3 | Arm A4 | Arm B4 | Arm A5 | Arm B5 |
|---|---|---|---|---|---|---|---|---|---|---|
| Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 9/23 | 7/22 | 6/16 | 5/15 | 6/15 | 2/15 | 7/12 | 5/10 | 7/19 | 7/19 |
| HydrocephalusNervous system disorders | 0/23 | 4/22 | 1/16 | 0/15 | 1/15 | 0/15 | 3/12 | 2/10 | 1/19 | 1/19 |
| PyrexiaGeneral disorders | 0/23 | 0/22 | 1/16 | 1/15 | 0/15 | 0/15 | 1/12 | 2/10 | 1/19 | 2/19 |
| HeadacheNervous system disorders | 1/23 | 2/22 | 0/16 | 2/15 | 1/15 | 1/15 | 1/12 | 2/10 | 1/19 | 2/19 |
| NauseaGastrointestinal disorders | 0/23 | 0/22 | 0/16 | 0/15 | 0/15 | 0/15 | 2/12 | 1/10 | 0/19 | 0/19 |
| VomitingGastrointestinal disorders | 0/23 | 3/22 | 1/16 | 2/15 | 0/15 | 1/15 | 2/12 | 1/10 | 1/19 | 1/19 |
| Tumour flareNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/23 | 3/22 | 0/16 | 1/15 | 0/15 | 0/15 | 0/12 | 0/10 | 0/19 | 0/19 |
| ColitisGastrointestinal disorders | 0/23 | 1/22 | 0/16 | 0/15 | 0/15 | 2/15 | 0/12 | 0/10 | 0/19 | 0/19 |
| Device related infectionInfections and infestations | 0/23 | 0/22 | 0/16 | 0/15 | 0/15 | 0/15 | 0/12 | 0/10 | 1/19 | 2/19 |
| Intracranial pressure increasedNervous system disorders | 0/23 | 0/22 | 1/16 | 1/15 | 1/15 | 0/15 | 0/12 | 0/10 | 2/19 | 1/19 |
| Event | Arm A1 | Arm B1 | Arm A2 | Arm B2 | Arm A3 | Arm B3 | Arm A4 | Arm B4 | Arm A5 | Arm B5 |
|---|---|---|---|---|---|---|---|---|---|---|
| HeadacheNervous system disorders | 9/23 | 10/22 | 7/16 | 2/15 | 7/15 | 6/15 | 5/12 | 2/10 | 13/19 | 5/19 |
| VomitingGastrointestinal disorders | 8/23 | 11/22 | 7/16 | 4/15 | 4/15 | 3/15 | 5/12 | 4/10 | 8/19 | 10/19 |
| NauseaGastrointestinal disorders | 8/23 | 4/22 | 4/16 | 4/15 | 1/15 | 3/15 | 4/12 | 1/10 | 3/19 | 5/19 |
| FatigueGeneral disorders | 8/23 | 6/22 | 4/16 | 3/15 | 2/15 | 4/15 | 2/12 | 1/10 | 5/19 | 4/19 |
| ConstipationGastrointestinal disorders | 5/23 | 5/22 | 5/16 | 5/15 | 0/15 | 3/15 | 1/12 | 2/10 | 5/19 | 4/19 |
| Aspartate aminotransferase increasedInvestigations | 2/23 | 4/22 | 2/16 | 2/15 | 1/15 | 5/15 | 1/12 | 1/10 | 4/19 | 1/19 |
| Abdominal painGastrointestinal disorders | 4/23 | 7/22 | 2/16 | 1/15 | 2/15 | 3/15 | 1/12 | 0/10 | 5/19 | 4/19 |
| Weight decreasedInvestigations | 3/23 | 7/22 | 1/16 | 0/15 | 2/15 | 1/15 | 1/12 | 0/10 | 0/19 | 2/19 |
| HemiparesisNervous system disorders | 4/23 | 7/22 | 0/16 | 0/15 | 0/15 | 0/15 | 0/12 | 1/10 | 1/19 | 0/19 |
| HypophosphataemiaMetabolism and nutrition disorders | 1/23 | 0/22 | 1/16 | 0/15 | 1/15 | 0/15 | 0/12 | 0/10 | 6/19 | 0/19 |
| Age, Customized(Participants) | Arm A1 | Arm B1 | Arm A2 | Arm B2 | Arm A3 | Arm B3 | Arm A4 | Arm B4 | Arm A5 | Arm B5 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| < 2 years old | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 3 |
| >= 2 and < 12 years old | 15 | 16 | 6 | 5 | 4 | 4 | 8 | 4 | 13 | 12 | 87 |
| >= 12 and < 18 years old | 6 | 5 | 6 | 8 | 11 | 9 | 3 | 3 | 4 | 6 | 61 |
| >= 18 years old | 2 | 1 | 4 | 2 | 0 | 2 | 1 | 2 | 1 | 0 | 15 |
| Sex: Female, Male(Participants) | Arm A1 | Arm B1 | Arm A2 | Arm B2 | Arm A3 | Arm B3 | Arm A4 | Arm B4 | Arm A5 | Arm B5 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 12 | 16 | 6 | 3 | 5 | 5 | 6 | 3 | 4 | 10 | 70 |
| Male | 11 | 6 | 10 | 12 | 10 | 10 | 6 | 7 | 15 | 9 | 96 |
| Ethnicity (NIH/OMB)(Participants) | Arm A1 | Arm B1 | Arm A2 | Arm B2 | Arm A3 | Arm B3 | Arm A4 | Arm B4 | Arm A5 | Arm B5 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 2 | 3 | 2 | 2 | 0 | 1 | 1 | 1 | 2 | 0 | 14 |
| Not Hispanic or Latino | 7 | 10 | 4 | 5 | 6 | 4 | 5 | 5 | 8 | 6 | 60 |
| Unknown or Not Reported | 14 | 9 | 10 | 8 | 9 | 10 | 6 | 4 | 9 | 13 | 92 |
| Race/Ethnicity, Customized(Participants) | Arm A1 | Arm B1 | Arm A2 | Arm B2 | Arm A3 | Arm B3 | Arm A4 | Arm B4 | Arm A5 | Arm B5 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| White | 19 | 11 | 13 | 14 | 14 | 14 | 7 | 9 | 18 | 13 | 132 |
| Black or African American | 2 | 4 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 9 |
| Asian | 0 | 2 | 1 | 1 | 0 | 0 | 3 | 1 | 0 | 2 | 10 |
| American Indian or Alaska Native | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other | 2 | 4 | 2 | 0 | 1 | 0 | 1 | 0 | 0 | 4 | 14 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jun 2017 to primary completion in Mar 2020, 32 months.
Results were first posted in Apr 2021, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Nivolumab · Ipilimumab